BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 16957494)

  • 1. Apparent transient effects of recent "ecstasy" use on cognitive performance and extrapyramidal signs in human subjects.
    Smith RM; Tivarus M; Campbell HL; Hillier A; Beversdorf DQ
    Cogn Behav Neurol; 2006 Sep; 19(3):157-64. PubMed ID: 16957494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?
    Morgan MJ; McFie L; Fleetwood H; Robinson JA
    Psychopharmacology (Berl); 2002 Jan; 159(3):294-303. PubMed ID: 11862362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users.
    Fox HC; McLean A; Turner JJ; Parrott AC; Rogers R; Sahakian BJ
    Psychopharmacology (Berl); 2002 Jul; 162(2):203-14. PubMed ID: 12110998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
    de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R
    J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self reported sleep quality and cognitive performance in ecstasy users.
    Montgomery C; Fisk JE; Wareing M; Murphy P
    Hum Psychopharmacol; 2007 Dec; 22(8):537-48. PubMed ID: 17960556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
    Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
    J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users.
    Gouzoulis-Mayfrank E; Thimm B; Rezk M; Hensen G; Daumann J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Aug; 27(5):819-27. PubMed ID: 12921915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol.
    Indlekofer F; Piechatzek M; Daamen M; Glasmacher C; Lieb R; Pfister H; Tucha O; Lange KW; Wittchen HU; Schütz CG
    J Psychopharmacol; 2009 Jul; 23(5):495-509. PubMed ID: 18635709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of stereotype threat on cognitive function in ecstasy users.
    Cole JC; Michailidou K; Jerome L; Sumnall HR
    J Psychopharmacol; 2006 Jul; 20(4):518-25. PubMed ID: 16174670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction.
    Quednow BB; Jessen F; Kuhn KU; Maier W; Daum I; Wagner M
    J Psychopharmacol; 2006 May; 20(3):373-84. PubMed ID: 16574711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ecstasy use and higher-level cognitive functions: weak effects of ecstasy after control for potential confounds.
    Bedi G; Redman J
    Psychol Med; 2008 Sep; 38(9):1319-30. PubMed ID: 18226286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for executive deficits among users of MDMA (Ecstasy).
    Fisk JE; Montgomery C; Murphy P; Wareing M
    Br J Psychol; 2004 Nov; 95(Pt 4):457-66. PubMed ID: 15527532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ecstasy (MDMA) exposure and neuropsychological functioning: a polydrug perspective.
    Medina KL; Shear PK; Corcoran K
    J Int Neuropsychol Soc; 2005 Oct; 11(6):753-65. PubMed ID: 16248911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurocognitive impairments in MDMA and other drug users: MDMA alone may not be a cognitive risk factor.
    Hanson KL; Luciana M
    J Clin Exp Neuropsychol; 2010 Apr; 32(4):337-49. PubMed ID: 20397296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The neuropsychology of ecstasy (MDMA) use: a quantitative review.
    Zakzanis KK; Campbell Z; Jovanovski D
    Hum Psychopharmacol; 2007 Oct; 22(7):427-35. PubMed ID: 17896346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neural mechanisms of working memory in ecstasy (MDMA) users who continue or discontinue ecstasy and amphetamine use: evidence from an 18-month longitudinal functional magnetic resonance imaging study.
    Daumann J; Fischermann T; Heekeren K; Thron A; Gouzoulis-Mayfrank E
    Biol Psychiatry; 2004 Sep; 56(5):349-55. PubMed ID: 15336517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An investigation of the subacute effects of ecstasy on neuropsychological performance, sleep and mood in regular ecstasy users.
    Pirona A; Morgan MJ
    J Psychopharmacol; 2010 Feb; 24(2):175-85. PubMed ID: 19351799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive performance in light current users and ex-users of ecstasy (MDMA) and controls.
    Golding JF; Groome DH; Rycroft N; Denton Z
    Am J Drug Alcohol Abuse; 2007; 33(2):301-7. PubMed ID: 17497553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.
    Reay JL; Hamilton C; Kennedy DO; Scholey AB
    J Psychopharmacol; 2006 May; 20(3):385-8. PubMed ID: 16574712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.